📰 Peter Griffith News
Peter Griffith News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Peter Griffith. Real-time updates on events, politics, business and more.
May 29, 2024
With the warm weather comes the return of local traditions such as Party in the Park, Concerts by the Shore, Food Truck Rodeo, Band on the Bricks, and more. Here's your guide:
February 29, 2024
THOUSAND OAKS, Calif., Feb. 29, 2024 /PRNewswire/ -- Amgen will present at the 44th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Tuesday, March 5, 2024. Peter Griffith, executive vice...
February 27, 2024
Tippi Hedren, 94, is battling dementia and time has taken its toll on the iconic screen star, her representatives confirmed.
February 15, 2024
Dakota Johnson is widely considered to be a gold standard nepo baby but just who is her famous family and what are they know for?
February 15, 2024
<strong>Brief letters: </strong>High-rise buildings | Brexit tackles | Evictions | Keir Starmer | Dear prudence
February 7, 2024
Amgen Inc. beats earnings expectations. Reported EPS is $4.71, expectations were $4.66.
February 7, 2024
Amgen is focused on price declines while it looks to fill out its portfolio and chase the new obesity market.
February 6, 2024
Amgen on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology companys October acquisition of rare disease drugmaker...
February 6, 2024
(Reuters) -Amgen on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics. For full-year 2024, the company said it expects adjusted earnings per share of $18.90 to $20.30 on revenue of $32.4 billion to $33.8 billion. "The guidance looks good and in line with consensus," Jefferies analyst Michael Yee said in an email.
February 6, 2024
(Reuters) -Amgen on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics. For full-year 2024, the company said it expects adjusted earnings per share of $18.90 to $20.30 on revenue of $32.4 billion to $33.8 billion. "The guidance looks good and in line with consensus," Jefferies analyst Michael Yee said in an email.